Applied Therapeutics, Inc. (APLT )

Currency in USD Disclaimer
$1.24 +$0.68 (121.35%)
Closed 09/26/2025
$0.57
$1.32
$0.3
$10.62

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APLT
  • Company Applied Therapeutics, Inc.
  • Price $1.24
  • Changes Percentage 121.35
  • Change 0.68
  • Day Low $0.57
  • Day High $1.32
  • Year High $10.62
  • Year Low $0.3
  • Market Cap $178,575,035
  • Price Avg 50 EMA (D) $0.49
  • Price Avg 200 EMA (D) $0.52
  • Exchange NASDAQ
  • Volume 104,815,954
  • Average Volume 3,021,109
  • Open $0.57
  • Previous Close $0.56
  • EPS -0.46
  • PE -2.70
  • Earnings Announcement 2025-11-13 20:00:00
  • Shares Outstanding $144,012,125

Company brief: APPLIED THERAPEUTICS, INC. (APLT )

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

APLT Corporation News

Income Statement